Abstract:Organic anion transporters (OATs) and organic anion-transporting polypeptides (OATPs), encoded by a number of solute carrier (SLC)22A and SLC organic anion (SLCO) genes, mediate the absorption and distribution of drugs and other xenobiotics. The regulation of OATs and OATPs is complex, comprising both transcriptional and post-translational mechanisms. Plasma membrane expression is required for cellular substrate influx by OATs/OATPs. Thus, interest in post-translational regulatory processes, including membrane targeting, endocytosis, recycling and degradation of transporter proteins, is increasing because these are critical for plasma membrane expression. After being synthesized, transporters undergo N-glycosylation in the endoplasmic reticulum and Golgi apparatus and are delivered to the plasma membrane by vesicular transport. Their expression at the cell surface is maintained by de novo synthesis and recycling, which occurs after clathrin- and/or caveolin-dependent endocytosis of existing protein. Several studies have shown that phosphorylation by signalling kinases is important for the internalization and recycling processes, although the transporter protein does not appear to be directly phosphorylated. After internalization, transporters that are targeted for degradation undergo ubiquitination, most likely on intracellular loop residues. Epigenetic mechanisms, including methylation of gene regulatory regions and transcription from alternate promoters, are also significant in the regulation of certain SLC22A/SLCO genes. The membrane expression of OATs/OATPs is dysregulated in disease, which affects drug efficacy and detoxification. Several transporters are expressed in the cytoplasmic subcompartment in disease states, which suggests that membrane targeting/internalization/recycling may be impaired. This article focuses on recent developments in OAT and OATP regulation, their dysregulation in disease and the significance for drug therapy.

An Overview of ABC and SLC Drug Transporter Gene Regulation

Post-translational modifications of transporters

Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs

Research progress in toxic effects of antitumor drugs based on drug transporter

The Important Role of Transporter Structures in Drug Disposition, Efficacy, and Toxicity.

The Role of ABCB1, ABCG2, and SLC Transporters in Pharmacokinetic Parameters of Selected Drugs and Their Involvement in Drug–Drug Interactions

The Physiological Role of Drug Transporters

The SLC transporter in nutrient and metabolic sensing, regulation, and drug development

Xenobiotic transporters: ascribing function from gene knockout and mutation studies.

ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology

Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly

Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease

Differential Expression of ABC Transporter Genes in Brain Vessels vs. Peripheral Tissues and Vessels from Human, Mouse and Rat

Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance

Regulation of the ATP-binding cassette transporters ABCB1, ABCG2 and ABCC5 by nuclear receptors in porcine blood-brain barrier endothelial cells

Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

The impact of ATP-binding cassette transporters on metabolic diseases

Epigenetic regulation of drug transporter expression in human tissues

The Solute Carrier Transporters and the Brain: Physiological and Pharmacological Implications.

Transcription factor-mediated regulation of the BCRP/ ABCG2 efflux transporter: a review across tissues and species